Immunotherapeutic peptide vaccination with leukemia-associated antigens

Current Opinion in Immunology

Volumn 18, Issue 5, 2006, Pages 599-604

  Rusakiewicz, Sylvie ^a   Molldrem, Jeffrey J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; LEUKEMIA ANTIGEN; PEPTIDE B2A2; PEPTIDE B3A2; PEPTIDE DERIVATIVE; QS 21; UNCLASSIFIED DRUG; VACCINE; VALYLLEUCYLGLUTAMINYLGLUTAMYLLEUCYLASPARAGINYLVALYLTHREONYLVALINE; WILM TUMOR ANTIGEN;

CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; LEUKEMIA; REVIEW; VACCINATION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA; VACCINES, SUBUNIT;

EID: 33748155666     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.07.005     Document Type: Review

References (49)

1. Barrett J., and Childs R. Non-myeloablative stem cell transplants. Br J Haematol 111 (2000) 6-17
2. Kolb H.J., Schmid C., Barrett A.J., and Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776
3. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K., Urbani E., Negrin R.S., Martelli M.F., and Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
4. Drobyski W.R., Gendelman M., Vodanovic-Jankovic S., and Gorski J. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. J Immunol 170 (2003) 3046-3053
5. Falkenburg J.H., van de Corput L., Marijt E.W., and Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 31 (2003) 743-751
6. Dickinson A.M., Wang X.N., Sviland L., Vyth-Dreese F.A., Jackson G.H., Schumacher T.N., Haanen J.B., Mutis T., and Goulmy E. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 8 (2002) 410-414
7. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., Goulmy E., Kester M.G., van der Hoorn M.A., van Luxemburg-Heys S.A., Hoogeboom M., Mutis T., Drijfhout J.W., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukaemia. Proc Natl Acad Sci USA 100 (2003) 2742-2747
8. Kloosterboer F.M., van Luxemburg-Heijs S.A., van Soest R.A., van Egmond H.M., Barbui A.M., Strijbosch M.P., Willemze R., and Falkenburg J.H. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNγ-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 19 (2005) 83-90
9. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S.Y., Sette A., and Scheinberg D.A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87 (1996) 3587-3592
10. Yotnda P., Firat H., Garcia-Pons F., Garcia Z., Gourru G., Vernant J.P., Lemonnier F.A., Leblond V., and Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101 (1998) 2290-2296
11. Osman Y., Takahashi M., Zheng Z., Koike T., Toba K., Liu A., Furukawa T., Aoki S., and Aizawa Y. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13 (1999) 166-174
12. Clark R.E., Dodi I.A., Hill S.C., Lill J.R., Aubert G., Macintyre A.R., Rojas J., Bourdon A., Bonner P.L., Wang L., et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98 (2001) 2887-2893
13. Butt N.M., Wang L., Abu-Eisha H.M., Christmas S.E., and Clark R.E. BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation. Blood 103 (2004) 3245
14. Westermann J., Schlimper C., Richter G., Mohm J., Dorken B., and Pezzutto A. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. Br J Haematol 125 (2004) 213-216
15. + T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 90 (2005) 1315-1323
16. Posthuma E.F., van Bergen C.A., Kester M.G., de Paus R.A., van Veelen P.A., de Ru A.H., Drijfhout J.W., Lurvink E.G., Willemze R., and Falkenburg J.H. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 89 (2004) 1062-1071. The authors show that, in contrast to Clark et al. [12], BCR-ABL peptide could not be detected from the surface of HLA-A*0301-transduced K562 cells. In addition, high-avidity BCR-ABL-specific T cells could not be isolated from antigen-primed healthy donors or CML patients in remission following DLI. The binding of BCR-ABL-specific T cells to the tetramer complexes was completely abrogated by anti-CD8 antibodies, which questions the T-cell epitope specific binding of these tetramer-positive cells.
17. Pinilla-Ibarz J., Korontsvit T., Zakhaleva V., Roberts W., and Scheinberg D.A. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 90 (2005) 1324-1332
18. Zhang P., Nelson E., Radomska H.S., Iwasaki-Arai J., Akashi K., Friedman A.D., and Tenen D.G. Induction of granulocytic differentiation by 2 pathways. Blood 99 (2002) 4406-4412
19. Barrett J., and Rezvani K. Neutrophil granule proteins as targets of leukemia-specific immune responses. Curr Opin Hematol 13 (2006) 15-20. This is a complete review on the nature and biology of proteinase 3 and neutrophil elastase as leukemia-specific immune responses.
20. Bories D., Raynal M.C., Solomon D.H., Darzynkiewicz Z., and Cayre Y.E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59 (1989) 959-968
21. Molldrem J., Dermime S., Parker K., Jiang Y.Z., Mavroudis D., Hensel N., Fukushima P., and Barrett A.J. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88 (1996) 2450-2457
22. Molldrem J.J., Clave E., Jiang Y.Z., Mavroudis D., Raptis A., Hensel N., Agarwala V., and Barrett A.J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90 (1997) 2529-2534
23. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., and Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59 (1999) 2675-2681
24. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., and Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000) 1018-1023
25. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S., Wang C., and Davis M.M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 111 (2003) 639-647
26. Gannage M., Abel M., Michallet A.S., Delluc S., Lambert M., Giraudier S., Kratzer R., Niedermann G., Saveanu L., Guilhot F., et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 174 (2005) 8210-8218. CML patients develop natural immunity to several leukemia-associated antigens. WT1, hTERT, PR1 and extrajunction BCR-specific T cells were detected in 60 to 85% of patients. These CTLs were shown to be quiescent unless appropriately stimulated. In addition, PR1, hTERT and BCR74 peptides, but not WT1 peptide, were detected from the surface of patient leukemia cells and by mass spectrometry analysis.
27. Inoue K., Tamaki H., Ogawa H., Oka Y., Soma T., Tatekawa T., Oji Y., Tsuboi A., Kim E.H., Kawakami M., et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91 (1998) 2969-2976
28. Bellantuono I., Gao L., Parry S., Marley S., Dazzi F., Apperley J., Goldman J.M., and Stauss H.J. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100 (2002) 3835-3837
29. Vonderheide R.H., Schultze J.L., Anderson K.S., Maecker B., Butler M.O., Xia Z., Kuroda M.J., von Bergwelt-Baildon M.S., Bedor M.M., Hoar K.M., et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 61 (2001) 8366-8370
30. Andersen M.H., Pedersen L.O., Capeller B., Brocker E.B., Becker J.C., and thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61 (2001) 5964-5968
31. Schmidt S.M., Schag K., Muller M.R., Weck M.M., Appel S., Kanz L., Grunebach F., and Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102 (2003) 571-576
32. Raptis A., Clave E., Mavroudis D., Molldrem J., Van Rhee F., and Barrett A.J. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells?. Br J Haematol 102 (1998) 1354-1358
33. Amrolia P.J., Reid S.D., Gao L., Schultheis B., Dotti G., Brenner M.K., Melo J.V., Goldman J.M., and Stauss H.J. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 101 (2003) 1007-1014
34. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., and Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100 (2002) 2132-2137
35. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102 (2003) 2892-2900
36. Rezvani K., Brenchley J.M., Price D.A., Kilical Y., Gostick E., Sewell A.K., Li J., Mielke S., Douek D.C., and Barrett A.J. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11 (2005) 8799-8807
37. Pinilla-Ibarz J., Cathcart K., Korontsvit T., Soignet S., Bocchia M., Caggiano J., Lai L., Jimenez J., Kolitz J., and Scheinberg D.A. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95 (2000) 1781-1787
38. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., and Scheinberg D.A. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 (2004) 1037-1042
39. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662. This paper shows the potential additive effect of molecular-targeted therapies and immunotherapy in CML patients. The vaccination with BCR-ABL peptides appeared to further improve patient clinical responses following imatinib or interferon-α treatments.
40. Qazilbash M.H., Wieder E., Rios R., Sijie L., Kant S., Giralt S., Estey E.H., Thall P., de Lima M., Couriel D., et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 104 (2004) (Abstract 259). Preliminary results of PR1-peptide vaccination of leukemia patients presented at the American Society of Hematology meeting available in abstract form.
41. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O.A., Oji Y., Kawakami M., Ikegame K., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 (2004) 13885-13890. These are the first reported clinical results of WT1 peptide vaccination in leukemia patients. AML, MDS but also breast and lung cancer patients were vaccinated with the HLA-A*2402-restricted native or altered WT1 peptide ligand and Montanide ISA51 adjuvant every two weeks. Although the authors ascribe alterations in percentage of blasts to clinical responses, all patients were in remission before vaccination. Therefore, it was not possible to link clinical response to measured immune responses.
42. Mailander V., Scheibenbogen C., Thiel E., Letsch A., Blau I.W., and Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 (2004) 165-166
43. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., and Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10 (2004) 4688-4698
44. Li Z., Qiao Y., Liu B., Laska E.J., Chakravarthi P., Kulko J.M., Bona R.D., Fang M., Hegde U., Moyo V., et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 11 (2005) 4460-4468. This paper reports the results of HSP70 peptide complex vaccine trial in CML patients that had not yet achieved a major cytogenetic response after six months of imatinib mesylate treatment. Following eight weekly intradermal injections of 50 μg autologous purified HSP70 peptide complex, nine out of sixteen patients assessed had an increased frequency of CML-specific interferon-γ-producing T cells and NK cells in the peripheral blood and these immunological responses were, in most cases, correlated with clinical responses. However, patients continued to receive imatinib mesylate and, thus, it is not clear whether HSP70 peptide complex has contributed to the overall clinical responses.
45. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746. This article presents the first human trial of CpG oligodeoxynucleotide 7909 combined with Melan-A peptide and incomplete Freund's adjuvant vaccination. Eight melanoma patients received four monthly vaccinations and showed no major side effects. The vaccination induced a rapid activation of effector memory Melan-A T cells, which were estimated to be at least one order of magnitude higher than reported in the previous vaccine trials. These CTLs specifically recognized and killed melanoma tumor cells. The observed immune responses were not correlated with clinical responses, but the authors notified that the follow-up time was probably too short (∼7 months).
46. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
47. Attia P., Phan G.Q., Maker A.V., Robinson M.R., Quezado M.M., Yang J.C., Sherry R.M., Topalian S.L., Kammula U.S., Royal R.E., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053. The authors reported the clinical results of 56 patients with progressive stage IV melanoma who received two modified gp100-melanoma-associated peptide in conjunction with human anti-CTLA-4 antibody. There was a strong correlation between the clinical responses and the induction of autoimmunity in patients.
48. - effector T cells.
49. 389 was infused before and omitted during the T cell priming phase.